ImmunoPET imaging of Trop2 in patients with solid tumours

Abstract

Accurately predicting and selecting patients who can benefit from targeted or immunotherapy is crucial for precision therapy. Trophoblast cell surface antigen 2 (Trop2) has been extensively investigated as a pan-cancer biomarker expressed in various tumours and plays a crucial role in tumorigenesis through multiple signalling pathways. Our laboratory successfully developed two 68Ga-labelled nanobody tracers that can rapidly and specifically target Trop2. Of the two tracers, [68Ga]Ga-NOTA-T4, demonstrated excellent pharmacokinetics in preclinical mouse models and a beagle dog. Moreover, [68Ga]Ga-NOTA-T4 immuno-positron emission tomography (immunoPET) allowed noninvasive visualisation of Trop2 heterogeneous and differential expression in preclinical solid tumour models and ten patients with solid tumours. [68Ga]Ga-NOTA-T4 immunoPET could facilitate clinical decision-making through patient stratification and response monitoring during Trop2-targeted therapies.

Trop2-targeted therapies in solid tumors: advances and future directions

“…Preclinical studies involving tumor-bearing mouse models and beagle dogs revealed good pharmacokinetics and diagnostic potential of the tracer. Moreover, in a pilot clinical trial involving patients with solid tumors, 68 Ga-NOTA-T4 immuno-PET noninvasively and accurately visualized varying Trop2 expression in primary and metastatic tumors 96 .…”